Adage Capital Partners
RPRX icon

Adage Capital Partners’s Royalty Pharma RPRX Stock Holding History

Adage Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$359M Sell
7,480,633
-4,259,961
-36% -$187M 0.55% 23
2025
Q4 		$454M Sell
11,740,594
-225,039
-2% -$8.58M 0.69% 16
2025
Q3 		$422M Buy
11,965,633
+5,965,633
+99% +$216M 0.67% 22
2025
Q2 		$216M Sell
6,000,000
-250,000
-4% -$8.28M 0.36% 43
2025
Q1 		$195M Sell
6,250,000
-10,718,321
-63% -$340M 0.36% 49
2024
Q4 		$433M Buy
16,968,321
+5,069,127
+43% +$134M 0.76% 18
2024
Q3 		$337M Buy
11,899,194
+967,263
+9% +$26.8M 0.59% 23
2024
Q2 		$288M Buy
10,931,931
+115,000
+1% +$3.19M 0.53% 24
2024
Q1 		$329M Sell
10,816,931
-80,000
-0.7% -$2.36M 0.62% 24
2023
Q4 		$306M Buy
10,896,931
+1,056,931
+11% +$29M 0.63% 23
2023
Q3 		$267M Buy
9,840,000
+1,190,000
+14% +$35.3M 0.61% 24
2023
Q2 		$266M Buy
8,650,000
+1,405,133
+19% +$47.6M 0.58% 24
2023
Q1 		$261M Buy
7,244,867
+244,867
+3% +$9.08M 0.59% 24
2022
Q4 		$277M Sell
7,000,000
-1,165,000
-14% -$48.6M 0.66% 19
2022
Q3 		$328M Sell
8,165,000
-8,542,815
-51% -$365M 0.81% 12
2022
Q2 		$702M Sell
16,707,815
-8,134,900
-33% -$333M 1.61% 4
2022
Q1 		$968M Hold
24,842,715
– – 1.84% 4
2021
Q4 		$990M Buy
24,842,715
+144,900
+0.6% +$5.63M 1.78% 4
2021
Q3 		$893M Buy
24,697,815
+1,976,000
+9% +$76.8M 1.76% 4
2021
Q2 		$931M Sell
22,721,815
-1,965,941
-8% -$83.6M 1.82% 5
2021
Q1 		$1.08B Sell
24,687,756
-14,026,524
-36% -$665M 2.2% 4
2020
Q4 		$1.94B Sell
38,714,280
-7,301,050
-16% -$310M 4.22% 2
2020
Q3 		$1.94B Hold
46,015,330
– – 4.85% 2
2020
Q2 		$2.23B Buy
+46,015,330
New +$2.28B 5.72% 1

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Adage Capital Partners's RPRX Position: Q1 2026 in Review

Adage Capital Partners reduced its Royalty Pharma (RPRX) stake by 36% in Q1 2026, selling an estimated $187M and leaving 7,480,633 shares worth $359M. The position accounts for 0.55% of the portfolio, ranked #23.

Adage Capital Partners first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. The position peaked at $2.23B in Q2 2020. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Adage Capital Partners held 7,480,633 shares of Royalty Pharma worth $359M as of Q1 2026.
  • Adage Capital Partners sold 4,259,961 Royalty Pharma shares in Q1 2026, an estimated $187M.
  • Royalty Pharma made up 0.55% of Adage Capital Partners's portfolio in Q1 2026, its #23 holding.
  • Adage Capital Partners first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • Adage Capital Partners's Royalty Pharma position peaked at $2.23B in Q2 2020.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.